Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate

Cancer Research

Volumn 54, Issue 17, 1994, Pages 4719-4725

  Zalutsky, Michael R ^a   McLendon, Roger E ^a   Garg, Pradeep K ^a   Archer, Gary E ^a   Schuster, James M ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ASTATOBENZOIC ACID AT 211; 3 ASTATOBENZOIC ACID N SUCCINIMIDYL ESTER AT 211; ASTATINE 211; BENZOIC ACID DERIVATIVE; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 45.6; MONOCLONAL ANTIBODY 81C6; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONJUGATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; INTRATHECAL DRUG ADMINISTRATION; ISOTOPE LABELING; MENINGITIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; RHABDOMYOSARCOMA; TISSUE DISTRIBUTION;

ALPHA PARTICLES; ANIMAL; ANTIBODIES, MONOCLONAL; ASTATINE; FEMALE; HUMAN; MENINGEAL NEOPLASMS; MENINGITIS; RADIOIMMUNOTHERAPY; RATS; RATS, NUDE; RHABDOMYOSARCOMA; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028017643     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bast, R. C., Jr. Zalutsky, M. R., and Frankel, A. Monoclonal antibodies. In: J.F. Holland, E. Frei III, R. C., Bast, Jr. D.W. Kufe, D. L., Morton, and R.R. Weichsel-baum (eds.), Cancer Medicine, Ed. 3, pp. 968-982. Philadelphia: Lea and Febiger, 1993.
2. Macklis, R. M., Kinsey, B. M., Kassis, A. I., Ferrara, J.L.M. Atcher, R. W., Hines, J. J., Coleman, C. N., Adelstein, S. J., and Burakoff, S. J., Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (Washington DC), 240: 1024-1026, 1988.
3. Brown, I. Astatine-211: its possible applications in cancer therapy. Appl. Radiat. Isot. 37: 789-798, 1986.
4. Hall, E. J., Radiobiology for the Radiologist, Ed. 3, pp. 161-177. Philadelphia: J.B. Lippincott Co. 1988.
5. Baxter, L. T., and Jain, R. K., Transport of fluid and macromolecules in tumors III. Role of binding and metabolism. Microvasc. Res. 41: 5-23, 1991.
6. Boucher, Y. Baxter, L. T., and Jain, R. K., Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50: 4478-4484, 1990.
7. van Osdol, W. Fujimori, K. and Weinstein, J. N., An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier”. Cancer Res. 51: 4776-4784, 1991.
8. Roeske, J. C., Chen, G.T.Y. Atcher, R. W., Pelizzari, C. A., Rotmensch, J. Haraf, D. Montag, A. and Weichselbaum, R. R., Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int. J. Radiat. Oncol. Biol. Phys. 19: 1539-1548, 1990.
9. Macklis, R. M., Kaplan, W. D., Ferrara, J.L.M. Atcher, R. W., Hines, J. J., Burakoff, S. J., and Coleman, C. N., Resident's essay award, alpha particle radio-immunotherapy: animal models and clinical prospects. Int. J. Radiat. Oncol. Biol. Phys. 16: 1377-1387, 1989.
10. Bloomer, W. D., McLaughlin, W. H., Lambrecht, R. M., Atcher, R. W., Mirzadeh, S. Madara, J. L., Milius, R. A., Zalutsky, M. R., Adelstein, S. J., and Wolf, A. P., 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 65Dy, and 90Y. Int. J. Radiat. Oncol. Biol. Phys. 10: 341-348, 1984.
11. Rotmensch, J. Atcher, R. W., Schlenker, R. Hines, J. Grdina, D. Block, B. S., Press, M. F., Herbst, A. L., and Weichselbaum, R. R., The effect of the α-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy. Gynecol. Oncol. 32: 236-239, 1989.
12. Vergote, I. B., Larsen, R. H., De Vos, L. N., Nesland, J. M., Bruland, Ø. S. Bjorgum, J. Alstad, J. Trope C.G. and Nustad, K. Therapeutic efficacy of the α-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model. Gynecol. Oncol. 47: 366-372, 1992.
13. Theodore, W. H., and Gendelman, S. Meningeal carcinomatosis. Arch. Neurol. 38: 696-699, 1981.
14. Ongerboer de Visser, B. W., Somers, R. Nooyen, W. H., van Heerde, P. Hart, A.A.M. and McVie, J. G., Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology, 33: 1565-1572, 1982.
15. Grossman, S. A., and Moynihan, T. J., Neoplastic meningitis. Neurol. Clin. 9: 843-856, 1991.
16. Fuchs, H. E., Archer, G. E., Colvin, O. M., Bigner, S. H., Schuster, J. M., Fuller, G. N., Muhlbaier, L. H., Schold, S. C., Jr. Friedman, H. S., and Bigner, D. D., Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res. 50: 1954-1959, 1990.
17. Bourdon, M. A., Matthews, T. J., Pizzo, S. V., and Bigner, D. D., Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J. Cell. Biochem. 28: 183-195, 1985.
18. Bourdon, M. Wikstrand, C. J., Furthmayr, H. Matthews, T. and Bigner, D. D., Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43: 2796-2805, 1983.
19. Zalutsky, M. R., Noska, M. A., Colapinto, E. V., Garg, P. K., and Bigner, D. D., Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res. 49: 5543-5549, 1989.
20. Zalutsky, M. R., Garg, P. K., Friedman, H. S., and Bigner, D. D., Labeling monoclonal antibodies and F(ab')2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA, 86: 7149-7153, 1989.
21. Garg, P. K., Archer, G. E., Jr. Bigner, D. D., and Zalutsky, M. R., Synthesis of radioiodinated W-succinimidyl iodobenzoate: optimization for use in antibody labeling. Int. J. Radiat. Appl. Instrum. Part A, 40: 485-490, 1989.
22. Stratton, M. R., Darling, J. Pilkington, G. J., Lantos, P. L., Reeves, B. R., and Cooper, C. S., Characterization of the human cell line TE-671. Carcinogenesis (Lond.), 10: 899-905, 1989.
23. Remington, R. D., and Schork, M. A., Statistics with Applications to the Biological and Health Sciences, Ed. 2, pp. 313-316. Englewood Cliffs, NJ: Prentice Hall, 1985.
24. Humm, J. L., Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med. 27: 1490-1497, 1986.
25. Humm, J. L., A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 13: 1767-1773, 1987.
26. Bloomer, W. D., McLaughlin, W. H., Neirinckx, R. D., Adelstein, S. J., Gordon, P. R., Ruth, T. J., and Wolf, A. P., Astatine-211-tellurium radiocolloid cures experimental malignant ascites. Science (Washington DC), 272; 340-341, 1981.
27. Link, E. M., and Carpenter, R. N., 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases. Cancer Res. 52: 4385-4390, 1992.
28. Harrison, A. and Royle, L. Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. Natl. Cancer Inst. Monogr. 3: 157-158, 1987.
29. Lashford, L. S., Davies, A. G., Richardson, R. B., Bourne, S. P., Bullimore, J. A., Eckert, H. Kemshead, J. T., and Coakham, H. B., A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer (Phila.), 61: 857-868, 1988.
30. Moseley, R. P., Benjamin, J. C., Ashpole, R. D., Sullivan, N. M., Bullimore, J. A., Coakham, H. B., and Kemshead, J. T., Carcinomatous meningitis: antibody-guided therapy with 1-131 HMFG1. J. Neurol. Neurosurg. Psychiatry, 54: 260-265, 1991.
31. Moseley, R. P., Papanastassiou, V. Zalutsky, M. R., Ashpole, R. D., Evans, S. Bigner, D. D., and Kemshead, J. T., Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int. J. Cancer, 52: 38-43, 1992.
32. Millar, W. T., and Barrett, A. Dosimetric model for antibody targeted radionuclide therapy of tumor cells in cerebrospinal fluid. Cancer Res. (Suppl.), 50: 1043s-1048s, 1990.
33. Lee, Y. Bullard, D. E., Humphrey, P. A., Colapinto, E. V., Friedman, H. S., Zalutsky, M. R., Coleman, R. E., and Bigner, D. D., Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. 48: 2904-2910, 1988.
34. Zalutsky, M. R., Moseley, R. P., Coakham, H. B., Coleman, R. E., and Bigner, D. D., Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 49: 2807-2813, 1989.
35. Schold, S. C., Jr. Zalutsky, M. R., Coleman, R. E., Glantz, M. J., Friedman, A. H., Jaszczak, R. J., Bigner, S. H., and Bigner, D. D., Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest. Radiol. 28: 488-496, 1993.
36. He, X. Archer, G. E., Wikstrand, C. J., Morrison, S. Zalutsky, M. R., Bigner, D. D., and Batra, S. K., Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J. Neuroimmunol. 52: 127-137, 1994.
37. Davson, H. Welch, K. and Segal, M. B., Physiology and Pathophysiology of the Cerebrospinal Fluid, pp. 200-201. Edinburgh: Churchill Livingstone, 1987.
38. Zalutsky, M. R., Schuster, J. M., Garg, P. K., Archer, G. E., Jr. Dewhirst, M. W., and Bigner, D. D., Two approaches for enhancing radioimmunotherapy: a emitters and hyperthermia. Recent Results Cancer Res. in press, 1994.
39. Baxter, L. T., and Jain, R. K., Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc. Res. 41: 252-272, 1991.
40. Yokota, T. Milenic, D. E., Whitlow, M. and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52: 3402-3408, 1992.
41. Hamilton, J. G., Durbin, P. W., and Parrott, M. The accumulation and destructive action of astatine211 (eka-iodine) in the thyroid gland of rats and monkeys. J. Clin. Endocrinol. Metab. 14: 1161-1174, 1954.
42. Roeske, J. C., and Chen, G.T.Y. A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors. Antibody Immunoconjugates Radiopharm. 4: 637-647, 1991.